Elsevier

Epilepsy & Behavior

Volume 7, Issue 2, September 2005, Pages 172-181
Epilepsy & Behavior

Review
The significance of folic acid for epilepsy patients

https://doi.org/10.1016/j.yebeh.2005.05.020Get rights and content

Abstract

The following is a comprehensive review of the current understanding of the many important roles of folic acid in the health of patients with epilepsy. A review of past and current literature reveals that folic acid plays important roles in the areas of hematology, neurology, development, and reproduction. Also highlighted are new areas for exploration.

Introduction

Initially, the hunt for the compound we now call folic acid was a quest to treat megaloblastic anemia. Under the microscope, the red blood cells in these forms of anemia were enlarged compared with normal red blood cells, and the anemias became known as megaloblastic anemias. These megaloblastic anemias were considered a significant health problem and several remedies were reported [1]. It was only later that some of the neurological conditions associated with folic acid deficiency, with or without anemia, came to the attention of neurologists [2].

The first published treatment of vitamin-deficiency anemia in humans was that by Willis in 1931. She reported an effective treatment derived from yeast for megaloblastic anemia in pregnant women in Bombay [3]. Large doses of liver were also demonstrated to be effective in the treatment of this anemia by Minot and Murphy [4], [5]. The missing vitamin was also referred to as vitamin M at one point [1].

Folic acid was isolated in pure crystalline form in 1941 [6]. Folic acid has received attention for its potential health benefits in vascular disease and birth defects. Evidence has emerged that folic acid may help prevent neural tube defects and, most recently, that it may have potential to reduce the risk of ischemic cerebrovascular disease and neurodegenerative disorders.

Section snippets

History of folic acid in neurology

Botez and Reynolds described the remarkable change in our perspective on the use of folic acid in neuropsychiatric diseases from the 1960s to the 21st century [7]. Reynolds and his co-workers reported the neuropsychiatric findings associated with the megaloblastic anemia caused by folic acid deficiency [2]. These include dementia, neuropathies, and a form of spinal degeneration called subacute combined degeneration. Folic acid deficiency may produce signs and symptoms identical to those of

Forms of folic acid

The word folic is derived from the Latin folium for “leaf,” as folic acid was first isolated from the leaves of a spinach plant [6]. Folic acid is composed of heterobicyclic pteridine and para-aminobenzoic acid (PABA), and is also known as pteroyl or pteroic acid. In plants, folic acid exists with a glutamic acid substituent (Fig. 1) The part of the structure in blue (A) in Fig. 1 is the heterobicyclic pteridine ring, and it is this portion of the molecule that carries the single carbon units.

Biochemical actions of folic acid

Folic acid in the form of tetrahydrofolate is a flexible carrier of activated one-carbon units. This cofactor is used in a number of important biochemical processes such as biosynthesis of amino acids and DNA synthesis and repair [12]. Tetrahydrofolate is also essential for formation of the amino acid glycine.

The one-carbon unit is bound to either the N-5 or N-10 nitrogen atom on one of the pteridine rings. Tetrahydrofolate can carry single carbon units (methyl units) on the pteridine ring

Conversion of homocysteine to methionine

Homocysteine is an amino acid derived entirely from the metabolism of methionine, an essential amino acid. Homocysteine is also an intermediary in synthesis of the amino acid cysteine. Homocysteine combines with serine to produce cysteine. A methyl group may be added back to homocysteine by tetrahydrofolic acid to produce methionine again. This process requires the presence of another cofactor, vitamin B12 (cobalamin), and the absence of either may result in megaloblastic anemia.

Epilepsy

According to Reynolds, folic acid began to develop a reputation for provoking seizures [15]. He states that concern emerged that folic acid might be a detriment to seizure control. This was not doubted, in large part due to experimental models that demonstrated that folic acid and some of its analogs were highly epileptogenic when injected into the third ventricles of rats [16]. Further, these researchers found that higher doses led to the death of the experimental animals.

A case report in 1960

Pregnancy and neural tube defects in patients with epilepsy

The first case report associating AEDs with birth defects was in 1963 [30]. This child was reportedly born with microcephaly, cleft palate, and a low IQ. Since that time numerous case reports have been published incriminating most AEDs. The FDA requires drug companies to list most AEDs as probable human teratogens in their package inserts.

It is fetal exposure to AEDs during the first trimester of pregnancy, specifically the 3rd through 10th weeks, that is of concern in the developing fetus [31]

Pathophysiology of neural tube defects

Neural tube defects encompass a variety of developmental problems including spina bifida and anencephaly, which are common congenital malformations. The incidence of these malformations is probably in the range of one per thousand births [40]. The process of neural tube closure involves several closure points. Disordered closure of any of these points can result in minor or major NTDs, which include exposure of the neural tissue to the outside environment or complete anencephaly.

The process of

Carbamazepine and neural tube defects

Numerous studies have demonstrated that carbamazepine is associated with an increased risk of birth defects including NTDs [38], [41]. One potential mechanism for this increased risk may lie in the fact that carbamazepine is an enzyme-inducing AED. Similar to phenytoin, phenobarbital, and primidone, carbamazepine induces the cytochrome P450 enzyme system. Enzyme-inducing AEDs have been demonstrated to decrease serum folic acid levels by increasing the metabolism of folic acid [48], [49], [50].

Valproic acid and neural tube defects

The evidence that valproic acid is a factor in NTDs is even more compelling [36], [41]. Unlike most of the older AEDs, valproic acid is responsible for only a small amount of induction of the cytochrome P450 enzymes. Valproic acid appears to interfere with folate metabolism [53], [54]. As noted earlier, folic acid is critical to the biosynthesis of DNA and RNA.

Homocysteine, folate, and associated neurological diseases

Recently interest has grown in the idea that elevated homocysteine concentrations might be an independent risk factor for vascular disease in humans. Because patients with epilepsy are more likely to be relatively deficient in folic acid or to have elevated homocysteine levels, these conditions are potentially of greater concern to patients with epilepsy than the general population [55], [56], [57].

Homocysteine is a sulfur-containing amino acid that can be cytotoxic, especially to endothelial

Vascular disease

Initial interest in homocysteine as a risk factor for vascular disease probably began with a case report of an infant who died of vascular disease and was found to have highly elevated levels of homocysteine due to an inborn error of metabolism [60]. Diaz-Arrastia, in a review of homocysteine and neurological disease [61], notes that this report was largely ignored for more that 20 years before studies such as the Framingham study corroborated homocysteine as an independent risk factor in

Homocysteine levels in epilepsy patients

For some time, epidemiological data have demonstrated that patients with epilepsy have higher mortality rates than age-matched controls. These rates are two to three times the rates of nonaffected peers [71]. Causes of this increased mortality include injuries from accidents, choking, status epilepticus, and sudden unexplained death in epilepsy (SUDEP), an incompletely explained tendency of patients to die from apparently natural causes at a higher rate than normal [72], [73]. One retrospective

Folic acid and dementia

A review by Mattson and Shea described how folic acid and homocysteine are implicated in several neurological diseases [78]. They cite evidence that folic acid might be important for DNA repair in postmitotic neurons. Further they state that homocysteine may induce damage in DNA of mature neurons, contributing to their damage and death. Possible explanations include increased oxidative stress from the homocysteine with increased intracellular calcium. Homocysteine may potentiate glutamate

Conclusions and future research directions

The importance of folic acid in the treatment of neurological diseases is now beyond question. Folic acid deficiency, once identified with anemia, is now associated with a wide range of neurological and vascular conditions that may be of greater concern in patients with epilepsy. From subacute combined degeneration to NTDs, researchers are identifying more links between folic acid and disease states. There is increasing interest in the mechanisms of disease caused by folic acid deficiency.

The

References (80)

  • M. Trotz et al.

    Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse

    Life Sci

    (1987)
  • T. Apeland et al.

    The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs

    Epilepsy Res

    (2002)
  • T. Apeland et al.

    Antiepileptic drugs as independent predictors of plasma total homocysteine levels

    Epilepsy Res

    (2001)
  • J. Selhub et al.

    The pathogenesis of homocysteinemia: interruption of the coordinated regulation by S-adenosylmethionine of the remethylation and trans-sulfuration of homocysteine

    Am J Clin Nutr

    (1992)
  • J.F. Toole

    Vitamin intervention for stroke prevention

    J Neurol Sci

    (2002)
  • T. Apeland et al.

    The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs

    Epilepsy Res

    (2002)
  • H. Karabiber et al.

    Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid

    Brain Dev

    (2003)
  • H. Ono et al.

    Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants

    Metabolism

    (1997)
  • M.P. Mattson et al.

    Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders

    Trends Neurosci

    (2003)
  • A. Coppen et al.

    Folic acid enhances lithium prophylaxis

    J Affect Disord

    (1986)
  • J.M. Vaughn

    The anaemias

    (1934)
  • E.H. Reynolds et al.

    Neurological disease associated with folate deficiency

    Br Med J

    (1973)
  • L. Wills

    Treatment of ‘pernicious anaemia of pregnancy’ and ‘tropical anaemia’ with special reference to yeast extract as curative agent

    Br Med J

    (1931)
  • G.R. Minot et al.

    Treatment of pernicious anemia by a special diet. 1926

    Yale J Biol Med

    (2001)
  • G.R. Minot et al.

    Landmark article (JAMA 1926): treatment of pernicious anemia by a special diet. By George R. Minot and William

    JAMA

    (1983)
  • H.K. Mitchell et al.

    The concentration of ‘folic acid’

    J Am Chem Soc

    (1941)
  • M.I. Botez et al.

    Folic acid, vitamin B12, and the nervous system: historical aspects

  • L.P. Rowland et al.

    Nutritional disorders: vitamin B12 deficiency, malabsorption and malnutrition

  • L. Stryer

    Biosynthesis of amino acids and heme

  • D.W. Martin

    Water-soluble vitamins

  • S.J. Benkovic

    On the mechanism of action of folate and biopterin-requiring enzymes

    Annu Rev Biochem

    (1980)
  • M.P. Mattson et al.

    Folate and homocysteine metabolism: therapeutic targets in cardiovascular and neurodegenerative disorders

    Curr Med Chem

    (2003)
  • J.M. Scott et al.

    Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry

    J Cardiovasc Risk

    (1998)
  • E.H. Reynolds

    Benefits and risks of folic acid to the nervous system

    J Neurol Neurosurg Psychiatry

    (2002)
  • M.S. Noell et al.

    Cerebral effects of folic acid, pyrimidines, amino acids and their antimetabolites

    Electroencephalogr Clin Neurophysiol

    (1960)
  • I. Chanarin et al.

    Megaloblastic anemia due to phenobarbitone: the convulsant action of therapeutic doses of folic acid

    Br Med J

    (1960)
  • L. Guidolin et al.

    Worsening in seizure frequency and severity in relation to folic acid administration

    Eur J Neurol

    (1998)
  • F. Matsuo et al.

    Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 05 Clinical Trial Group

    Neurology

    (1993)
  • A. Richens et al.

    Overview of the clinical efficacy of lamotrigine

    Epilepsia

    (1991)
  • Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of...

    • Cited by (22)

    • The impact of early-life environment on absence epilepsy and neuropsychiatric comorbidities

      2022, IBRO Neuroscience Reports

    • Improving Folic Acid Supplementation Rates in Women of Childbearing Age With Epilepsy

      2018, Pediatric Neurology
      Citation Excerpt :

      The average rate of major congenital malformation among all AED exposures varies between 3% and 9%, approximately two- to threefold higher than the general population.5-7 A wide variety of malformations have been reported in children of WWE including neural tube defects, orofacial clefts, urogenital defects, and congenital heart disease, and almost every AED has been implicated in their development.8-10 Several mechanisms for AED-related teratogenicity, including folate deficiency, have been proposed, although remain unclear.8

    • MTHFR, MTR, and MTHFD1 gene polymorphisms compared to homocysteine and asymmetric dimethylarginine concentrations and their metabolites in epileptic patients treated with antiepileptic drugs

      2011, Seizure
      Citation Excerpt :

      This is demonstrated by studies conducted on a Greek population, in epileptic children aged 4.5–14 years treated by AEDs for 20 weeks,5 by studies conducted on epileptic adult patients treated with AEDs in mono- and polytherapy for over 30 days.6 The generation of Hcy in epileptic patients, as demonstrated by the literature, is related both to AEDs [such as phenytoin, phenobarbital, primidone, and carbamazepine (CBZ)] inducing microsomal liver enzymes and increasing cytochrome P450 enzyme activity, which leads to a decrease in FA serum concentration, as well as AEDs [such as valproic acid (VPA)] that induce liver enzymes to a smaller degree and have a lesser effect on the concentration of FA in blood serum.32 An increase in Hcy and accompanying decrease in FA concentration in epileptic patients after receiving CBZ was demonstrated in the studies by Verrotti et al.,3 Karabiber et al.4 and Attilakos et al.5 In epileptics taking VPA, an increase in Hcy concentration was demonstrated both accompanying a decrease in FA3,4 and without FA changes.5

    • A review of the effects of vitamins and other dietary supplements on seizure activity

      2010, Epilepsy and Behavior
      Citation Excerpt :

      Although n-3 PUFA supplementation is safely used in treating cardiovascular disease, there is not yet enough evidence to support its use for the treatment of epilepsy. Folic acid is composed of the heterobicyclic pteridine and para-aminobenzoic acid (PABA) [44]. Most animals and humans cannot synthesize PABA and, therefore, are unable to manufacture folic acid.

    • Gollop-Wolfgang Complex in a baby born to an epileptic mother treated with valproic acid during pregnancy

      2010, Farmacia Hospitalaria

    • Imprinted polymer-carbon consolidated composite fiber sensor for substrate-selective electrochemical sensing of folic acid

      2010, Biosensors and Bioelectronics
    View all citing articles on Scopus
    View full text
    Copyright © 2005 Elsevier Inc. All rights reserved.